Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People

HIV Clinical Trial

— ALT-803  

Official title:

Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People on Optimized ART With Undetectable Plasma HIV RNA

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02191098
• Other study ID #: 1508M77601-1
• Status: Completed
• Phase: Phase 1
• Start date: June 2015
• Est. completion date: September 9, 2019

Study information

• Verified date: January 2020
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the safety and tolerability of ALT-803, as well as, the potential efficacy of ALT-803 in HIV

Description:

This is an open-label, single-arm intra-patient dose escalating pilot study of ALT-803, a recombinant human super agonist interleukin-15 (IL-15) complex with an expansion cohort at the maximum tolerated dose (MTD). The primary aim is to investigate the safety and tolerability of ALT-803 in HIV-infected people receiving potent and optimized antiretroviral therapy. All infusions will occur on a Monday. Subjects will be monitored for 24 hours after the first infusion and then for 6 hours after each subsequent infusion, provided no unacceptable toxicity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: September 9, 2019
• Est. primary completion date: September 9, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

1. HIV-1 infected adults aged 18 years or over.

2. Stable ART for at least 36 months

3. Screening plasma HIV RNA levels below level of quantification (<40 to <50 copies RNA/mL depending on the assay) = 2 years (a single measurement above the level of detection but < 100-200 copies/ml will be allowed)

4. Screening CD4 count =500 cells/mm3

5. Laboratory tests performed within 14 days of study enrollment:

1. WBC = 3000/mm3

2. Platelets = 50,000/mm3 [Patients may be transfused to meet this requirement]

3. Hemoglobin = 8 g/dL (>80g/L) [Patients may be transfused to meet this requirement]

4. Calculated glomerular filtration rate (GFR) >45 mL/min/1.73m2

5. Total bilirubin = 2.0 X upper limit of institutional normal (ULN)

6. AST, ALT, ALP = 2.0 X ULN

6. Adequate pulmonary function without any clinical sign of severe pulmonary dysfunction. PFTs > 50% of predicted if symptomatic or prior known impairment.

7. Ability to be off prednisone and other immunosuppressive drugs for at least 14 days before first dose of study drug

8. Women of child bearing potential and men with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy

9. Voluntary written consent

Exclusion Criteria:

1. Active infection other than HIV currently requiring systemic antimicrobial therapy

2. Previously treated on this study or received previous ALT-803

3. Latent TB infection or active TB disease prior to completing a standard regimen of anti-TB therapy

4. Active fungal infection requiring systemic antifungal therapy

5. Active or recurrent herpes or varicella-zoster virus infection requiring treatment (or chronic suppression)

6. Chronic hepatitis B or C

7. Planning or current pregnancy or breastfeeding

8. Intended modification of antiretroviral therapy in the next 24 weeks

9. NYHA (New York Heart Association) Class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, or other clinical signs of severe cardiac dysfunction

10. Symptomatic congestive heart failure, unstable angina pectoris, or Myocardial infarction within 6 months prior to screening

11. Marked baseline prolongation of QT/QTc interval (e.g. demonstration of a QTc interval greater than 500 milliseconds)

12. History or evidence of uncontrollable CNS disease

13. Prior organ allograft or allogeneic transplantation

14. On-going chronic systemic or regular inhaled corticosteroid use or other immunosuppressive therapy (a history of mild asthma not requiring therapy is eligible)

15. Psychiatric illness/social situations that would limit compliance with study requirements

16. Other illness that in the opinion of the investigator would exclude the patient from participating in this study

Related Conditions & MeSH terms

• HIV
• Stable ART

Intervention

Drug:
• ALT-803
Interleukin 15 (IL-15) is a common ?-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells

Locations

Country	Name	City	State
United States	University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the safety and tolerability of ALT-803 in HIV-infected subjects	Safety and tolerability is determined by the incidence of adverse events, size of the inducible reservoir as estimated using the TILDA assay	4 weeks
Secondary	Assess the impact of ALT-803 on the size of the inducible reservoir,	Assess the impact of ALT-803 on the size of the inducible reservoir, as estimated using the TILDA assay, in total CD4+ T cells and memory subsets	4 weeks